Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036335 · ClinicalTrials.gov registry record · Phase 3
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT00036335: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00036335 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 286 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036335, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side effects that might be associated with it.
Interventions
- DRUG Duloxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
What the finished NCT00036335 record still lists
NCT00036335 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which Duloxetine Hydrochloride is the first listed.
NCT00036335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036335 about?
NCT00036335 is a clinical study titled "Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain". The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side effects that might be associated with it.
What is the current status of trial NCT00036335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2002-03. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036335?
The interventions under investigation include: Duloxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00036335?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036335's enrollment target sits among peer trials
286 1182nd of 2000 higher than 816 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia